Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 14/20 | 0.54 |
| ▸ | CALCR | P30988 | 14/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593288 | 0.89 | C5AR1 (0.63) | CXCR4 | |
| SCHEMBL30646311 | 0.87 | APLNR (0.58) | RAMP3CALCRAPLNR | |
| SCHEMBL29416007 | 0.87 | APLNR (0.58) | RAMP3CALCRAPLNR | |
| SCHEMBL29566093 | 0.87 | RAMP3 (0.57) | RAMP3CALCRCXCR4 | |
| SCHEMBL29608877 | 0.86 | APLNR (0.50) | RAMP3CALCRAPLNRPLK1 | |
| SCHEMBL30883197 | 0.85 | APLNR (0.54) | RAMP3CALCRAPLNROPRM1OPRK1 | |
| SCHEMBL30537453 | 0.85 | CXCR4 (0.57) | APLNROPRM1OPRK1CXCR4 | |
| SCHEMBL29608399 | 0.85 | NTSR2 (0.55) | APLNR | |
| SCHEMBL30537456 | 0.85 | APLNR (0.55) | APLNROPRM1OPRK1CXCR4 | |
| SCHEMBL29607182 | 0.84 | C5AR1 (0.56) | APLNROPRM1OPRK1CXCR4PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | RAMP3 3434/4885CALCR 3230/4885APLNR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.